Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | BMC Gastroenterology

Fig. 1

From: Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

Fig. 1

Kaplan-Meier curve of overall survival time (a) and PFS time (b) by treatments. a The estimated median overall survival time was derived as 37 months (95%CI = 32.2–41.8 months) for cTACE and 37 months (95%CI = 23.5–50.5 months) for DEB-TACE. The log-rank test p-value = 0.091. b The estimated median PFS time was derived as 11 months (95%CI = 9.6–12.4 months) for cTACE and 16 months (95%CI = 13.1–18.9 months) for DEB-TACE. The log-rank test p-value = 0.019

Back to article page